HREVS: Hybrid Revascularization Offers No Advantage in Multivessel Disease

Courtesy of SBHCI.

Hybrid revascularization, which combines CABG with PCI, failed to reduce myocardial ischemia and major cardiac and cerebrovascular events, compared to cardiac artery bypass graft  or PCI separately.

HREVS: la revascularización híbrida no ofrece ventajas en la enfermedad de múltiples vasos

However, this small study does not provide conclusive evidence, which calls for further randomized studies with enough statistical power to answer this question. Fortunately, we won’t have to wait long, since at   present there the HYBRID study is in progress, with a 5 year follow up and more than 2300 patients with multivessel disease randomized to hybrid revascularization vs. PCI.


Read also: CULPRIT-SHOCK Results Will Transform Guidelines and Clinical Practice”.


The small HREVS study included 155 patients (50 undergoing surgery alone, 53 PCI alone and 52 hybrid revascularization). Hybrid revascularization included minimally invasive surgery with mammary bypass to the anterior descending artery, followed by PCI between 1 and 3 days after, with DES to all remaining vessels.

 

The study did not have power to show clinical end points, but there were significant differences at 30 days.

 

Gentileza de la SBHCI.

 

Original title: HREVS: a randomized trial of PCI vs CABG vs hybrid revascularization in patients with coronary artery disease.

Presenter: Tarasov R.

 

HREVS-study


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....